Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C71H110N28O13 |
| Molecular Weight | 1563.8129 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC2=CNC=N2)C(=O)NCC(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CNC=N5)C(N)=O
InChI
InChIKey=UIBPZXXSPHGPDS-GUBPWTFESA-N
InChI=1S/C71H110N28O13/c1-41(75)60(103)91-48(15-5-8-24-72)62(105)94-52(19-12-28-85-71(79)80)66(109)99-57(33-46-36-83-40-89-46)69(112)98-56(32-45-35-82-39-88-45)61(104)86-37-58(101)90-54(30-43-20-22-47(100)23-21-43)67(110)95-49(16-6-9-25-73)63(106)93-51(18-11-27-84-70(77)78)64(107)92-50(17-7-10-26-74)65(108)97-55(29-42-13-3-2-4-14-42)68(111)96-53(59(76)102)31-44-34-81-38-87-44/h2-4,13-14,20-23,34-36,38-41,48-57,100H,5-12,15-19,24-33,37,72-75H2,1H3,(H2,76,102)(H,81,87)(H,82,88)(H,83,89)(H,86,104)(H,90,101)(H,91,103)(H,92,107)(H,93,106)(H,94,105)(H,95,110)(H,96,111)(H,97,108)(H,98,112)(H,99,109)(H4,77,78,84)(H4,79,80,85)/t41-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-/m0/s1
| Molecular Formula | C71H110N28O13 |
| Molecular Weight | 1563.8129 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 7 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Intracellular angiotensin II activates rat myometrium. | 2011-09 |
|
| Paraquat increases connective tissue growth factor and collagen expression via angiotensin signaling pathway in human lung fibroblasts. | 2010-04 |
|
| Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells. | 2001-03 |
|
| Role of central ANG II receptors in stress-induced cardiovascular and hyperthermic responses in rats. | 1997-01 |
|
| Angiotensin II antagonists. | 1993-11 |
|
| Characterization of alterations of hemodynamics and neuroendocrine hormones in dexamethasone induced hypertension in dogs. | 1991 |
|
| Identification of angiotensin II receptor subtypes. | 1989-11-30 |
|
| [Etiological studies of secondary hypertension. e. Drug-induced hypertension]. | 1984-02 |
|
| Role of the anteroventral third ventricle region and the renin angiotensin system in methylprednisolone hypertension. | 1981-11-01 |
|
| Etiopathogenesis of excess methylprednisolone arterial hypertension in the rat. | 1981 |
|
| Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats. | 1980-02 |
|
| Dopamine and saralasin antagonism of renal vasoconstriction and oliguria caused by amphotericin B in dogs. | 1979-10 |
|
| Effect of Sar1-ala8-angiotensin II on blood pressure and renin in Bartter's syndrome, before and after treatment with prostaglandin synthetase inhibitors. | 1979-10 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:07:24 GMT 2025
by
admin
on
Mon Mar 31 18:07:24 GMT 2025
|
| Record UNII |
B6WQB8NCPA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
B6WQB8NCPA
Created by
admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
|
PRIMARY | |||
|
16138585
Created by
admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
|
PRIMARY | |||
|
190673-58-6
Created by
admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
